1. Home
  2. USAS vs NTLA Comparison

USAS vs NTLA Comparison

Compare USAS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • USAS
  • NTLA
  • Stock Information
  • Founded
  • USAS 1998
  • NTLA 2014
  • Country
  • USAS Canada
  • NTLA United States
  • Employees
  • USAS N/A
  • NTLA N/A
  • Industry
  • USAS Metal Mining
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • USAS Basic Materials
  • NTLA Health Care
  • Exchange
  • USAS Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • USAS 1.1B
  • NTLA 1.2B
  • IPO Year
  • USAS N/A
  • NTLA 2016
  • Fundamental
  • Price
  • USAS $4.05
  • NTLA $12.14
  • Analyst Decision
  • USAS Strong Buy
  • NTLA Buy
  • Analyst Count
  • USAS 2
  • NTLA 20
  • Target Price
  • USAS $3.33
  • NTLA $25.83
  • AVG Volume (30 Days)
  • USAS 3.5M
  • NTLA 9.7M
  • Earning Date
  • USAS 11-11-2025
  • NTLA 11-06-2025
  • Dividend Yield
  • USAS N/A
  • NTLA N/A
  • EPS Growth
  • USAS N/A
  • NTLA N/A
  • EPS
  • USAS N/A
  • NTLA N/A
  • Revenue
  • USAS $96,597,000.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • USAS $25.34
  • NTLA $9.20
  • Revenue Next Year
  • USAS $84.70
  • NTLA N/A
  • P/E Ratio
  • USAS N/A
  • NTLA N/A
  • Revenue Growth
  • USAS N/A
  • NTLA 14.99
  • 52 Week Low
  • USAS $0.80
  • NTLA $5.90
  • 52 Week High
  • USAS $5.12
  • NTLA $28.25
  • Technical
  • Relative Strength Index (RSI)
  • USAS 54.19
  • NTLA 32.04
  • Support Level
  • USAS $3.71
  • NTLA $13.21
  • Resistance Level
  • USAS $4.25
  • NTLA $26.35
  • Average True Range (ATR)
  • USAS 0.31
  • NTLA 1.91
  • MACD
  • USAS -0.12
  • NTLA -1.94
  • Stochastic Oscillator
  • USAS 24.11
  • NTLA 3.07

About USAS Americas Gold and Silver Corporation no par value

Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: